Division of Colorectal Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin.
Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
J Surg Res. 2020 Jan;245:434-440. doi: 10.1016/j.jss.2019.07.020. Epub 2019 Aug 21.
Magnetic resonance imaging (MRI) has become the preferred method for local staging of rectal cancer. Current MRI technology, operating at 1.5-3 T, results in incorrectly reported tumor depth and therefore inaccurate staging in one-third of individuals. Inaccurate staging can result in suboptimal treatment in patients with rectal cancer and can submit them to unnecessary treatments. The Medical College of Wisconsin Center for Imaging Research houses one of approximately twenty experimental 7 T MRIs worldwide capable of imaging the human pelvis. We present our initial experience with this novel imaging technique for the human rectum.
This was a prospective observational trial conducted at a single institution. Patients diagnosed with rectal cancer and who underwent low anterior resection or abdominoperineal resection between July 2015 and July 2017 were included. Excised rectal specimens were suspended in a saline-filled container and imaged by MRI at 7T. Tumor depth and lymph node status were determined by a single radiologist who was blinded to the pathologic results. These MRI interpretations were then compared with the pathologic stage.
Seven of the 10 patients received neoadjuvant chemoradiation. When using the T1-weighted volumetric interpolated breath-hold examination-flex fat-suppressed sequences, radiologic and pathologic interpretation was identical regarding tumor depth in 7 of 10 patients (70%). Nodal status was correctly interpreted by 7T MRI in 8 of 10 patients (80%). Lymph nodes as small as 2 mm were able to be correctly characterized as harboring malignancy.
We have demonstrated that 7T MRI of the rectum ex vivo has a strong correlation with histologic results. With its superior signal-to-noise ratio and spatial resolution, 7T MRI holds promise in more accurately staging rectal cancer and may be useful in correctly categorizing response to neoadjuvant therapy.
磁共振成像(MRI)已成为直肠癌局部分期的首选方法。目前的 1.5-3T MRI 技术导致三分之一的个体肿瘤深度报告不正确,从而导致分期不准确。分期不准确可能导致直肠癌患者治疗效果不佳,并使他们接受不必要的治疗。威斯康星医学院影像研究中心拥有大约二十台可对人体骨盆进行成像的实验性 7T MRI 之一。我们介绍了这种新型成像技术在人体直肠中的初步应用经验。
这是一项在一家机构进行的前瞻性观察性试验。纳入 2015 年 7 月至 2017 年 7 月期间接受低位前切除术或腹会阴切除术的直肠癌患者。切除的直肠标本悬挂在充满生理盐水的容器中,并在 7T 下进行 MRI 成像。由一名对病理结果不知情的放射科医生确定肿瘤深度和淋巴结状态。然后将这些 MRI 解释与病理分期进行比较。
10 例患者中有 7 例接受了新辅助放化疗。当使用 T1 加权容积内插屏气检查-脂肪抑制序列时,7 例患者中的 10 例(70%)MRI 对肿瘤深度的解释与病理结果一致。7T MRI 正确解释了 10 例患者中的 8 例(80%)的淋巴结状态。小至 2 毫米的淋巴结也能够正确地被描述为恶性。
我们已经证明,直肠离体 7T MRI 与组织学结果具有很强的相关性。由于其具有更高的信噪比和空间分辨率,7T MRI 有望更准确地分期直肠癌,并可能有助于正确分类新辅助治疗的反应。